Screener / SEC EDGAR /CIK 0000914156 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

UFP Technologies Inc UFPT

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 27, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+38.0%

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+19.5%

“The increase in net sales is primarily due to increased sales to customers in the medical market of 23.2%.”

Read it in the 10-K

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+15.8%

“The decrease in the effective tax rate for the current period as compared to the prior period is largely due to a shift in mix or pre-tax income to jurisdictions where we are taxed at a favorable rate as well as increased discrete tax benefits associated with vested equity and a state tax refund.”

Read it in the 10-K

Gross margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

29.1% to 28.3% (-0.8 pts)

The MD&A has no sentence that names a cause for this change.

Operating margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

16.0% to 15.3% (-0.7 pts)

The MD&A has no sentence that names a cause for this change.

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +19.5%

    “The increase in net sales is primarily due to increased sales to customers in the medical market of 23.2%.”

    Read it in the FY 2025 10-K
  • FY 2024 +26.1%

    “We attribute the increase in net sales primarily to increased net sales from newly acquired companies of $70.3 million as well as 8.5% increased organic net sales fueled by increases in the robotic surgery and infection prevention markets.”

    Read it in the FY 2024 10-K

    “As a percentage of net sales, SG&A decreased to 12.3% for the year ended December 31, 2024, from 12.7% for the same period in 2023 reflecting the leverage of the net sales increase over relatively fixed SG&A.”

    Read it in the FY 2024 10-K

Gross margin

1 of 2 years explained
  • FY 2025 -0.8 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +1.0 pts

    “We attribute the increase in gross margin primarily to the accretive margins from the Company’s recent acquisitions as well as increased manufacturing efficiencies and the containment of fixed overhead costs.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 -0.7 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +1.6 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Net income

2 of 2 years explained
  • FY 2025 +15.8%

    “The decrease in the effective tax rate for the current period as compared to the prior period is largely due to a shift in mix or pre-tax income to jurisdictions where we are taxed at a favorable rate as well as increased discrete tax benefits associated with vested equity and a state tax refund.”

    Read it in the FY 2025 10-K
  • FY 2024 +31.3%

    “The increase in the effective tax rate for the current period as compared to the prior period is largely due to the difference in discrete items during the two periods as well as more United States based income in 2024 as a result of the recent acquisitions.”

    Read it in the FY 2024 10-K

Cash from operations

0 of 2 years explained
  • FY 2025 +38.0%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +61.1%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UFPT/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.